Three Different Presentation of Same Pathophysiology
AlGherbawe Mushtak, Fahmi Yousef Khan, Baidaa AlDehwe, Ahmed Abdulrahman Al-Ani
Acta Inform Med. 2012; 20(3): 190-191
We report three male patients of younger age group presented with acute vein thrombosis of different sites, right lower limb, cortical venous sinuses thrombosis with cerebral vascular accident and third case is mesenteric vein thrombosis. All patients were Vegetarian, had low level of cobalamin with marked hyper homocysteinemia with normal serum and red cell folic acid. The low Cobalamin level was not suspected secondary to pernicious anemia, based on the fact that there was no evidence of atrophic gastritis and an absence of antiparietal cell antibodies. There were no evident of immobilization, recent surgery, malignancy, antiphospholipid antibody, myeloproliferative disorder, and hormone replacement therapy. No deficiencies in protein C, protein S, or antithrombin III, normal factor V Leiden, no prothrombin gene mutation 20210A and no clone for paroxysmal nocturnal hemoglobinurea were detected, no cause was found for the thrombosis apart from their secondary hyperhomocysteinemia.
1. Remacha AF, Souto JC, Ramila E, Perea G, Sarda MP, Fontcuberta J. Enhanced risk of thrombotic disease in patients with acquired vitamin B12 and/or folate deficiency: role of hyperhomocysteinemia. Ann Hematol. 2002; 81: 616-621.
2. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet WS, Sly S, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill, 1989: 693-734.
3. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A. et al. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993; 39: 1764-1779.
4. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268: 877-881.
5. Homocysteine Studies Collaboration. Homocysteine and Risk of Ischemic Heart Disease and Stroke. JAMA. 2002; 288(16): 2015-2022.
6. Frederiksen J, Juul K, Grande P. et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood. 2004; 10: 3046-3051.
7. den Heijer M, Rosendaal FR, Blom HJ. et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998; 80: 874-877.
8. Brattström L, Tengborn L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis. 1991; 21: 51-57.
9. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters. Thromb Res. 1993; 70: 123-129.
10. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994; 14: 1080-1083.
11. Amundsen TO, Ueland MG, Waage AN. Plasma Homocysteine Levels in Patients with Deep Venous Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995; 15: 1321-1323.
12. Ducros V, Barro C, Yver J, Pernod G, Polack B et al. Should Plasma Homocysteine Be Used as a Biomarker of Venous thromboembolism? A Case-Control Study. Clinical and Applied Thrombosis/Hemostasis. 2009; 15(5): 517-522.